Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELESTRIN vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol is a hormone that binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, leading to effects such as endometrial growth, breast development, and regulation of the menstrual cycle. It also has non-genomic actions via membrane-associated estrogen receptors.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis,Off-label: Treatment of menopausal depression, urogenital atrophy
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Apply 1.25 g (2 actuations) of 0.06% gel to upper arm/shoulder once daily; may adjust based on response.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life of estradiol is approximately 13-16 hours. Steady-state concentrations are achieved after 2-4 days of daily application. Clinical context: The half-life supports once-daily dosing for transdermal delivery.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation. Metabolites include estrone and estriol, which are conjugated with sulfate or glucuronide and excreted in urine.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Estradiol (active metabolite of estradiol hemihydrate) is primarily excreted in urine as glucuronide and sulfate conjugates (approximately 60-80%), with about 10% excreted in feces via bile. Unchanged estradiol excretion is minimal.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Estradiol is 97.5-99% bound to plasma proteins, primarily albumin (60-70%) and sex hormone-binding globulin (SHBG, 30-40%).
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Volume of distribution of estradiol is approximately 1.2 L/kg (range 0.9-1.5 L/kg). This high Vd indicates extensive tissue distribution and binding, including to estrogen receptors in target organs.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Transdermal gel: Bioavailability is approximately 3-5% compared to intravenous administration due to skin metabolism and retention. The absolute bioavailability via the transdermal route is 82% relative to a reference transdermal delivery system. Oral estradiol has low bioavailability (5-10%) due to first-pass metabolism.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
No specific dose adjustment provided; use with caution in severe renal impairment.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Contraindicated in severe hepatic disease (Child-Pugh class C); use with caution in mild to moderate impairment.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Not recommended for use in pediatric patients; safety and efficacy not established.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Use with caution; consider lower starting dose due to increased risk of adverse effects.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of endometrial cancer, breast cancer, stroke, and pulmonary embolism have been reported. Use with progestin in women with an intact uterus reduces risk of endometrial hyperplasia/carcinoma.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Risk of endometrial cancer: Use adequate progestin in women with an intact uterus,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, MI, especially in smokers and women with hypertension,Breast cancer: Increased risk with prolonged use, especially with combination therapy,Dementia: Increased risk in women over 65,Gallbladder disease: Increased risk,Hypertriglyceridemia: May occur, caution in patients with elevated triglycerides,Hepatic impairment: Use caution, monitor liver function,Hypothyroidism: May increase thyroid-binding globulin, adjust thyroid replacement,Fluid retention: Use caution in conditions affected by edema,Hypocalcemia: Use caution in patients with hypoparathyroidism,Ovarian cancer: Possibly increased risk with estrogen-alone use,Exacerbation of endometriosis,Hereditary angioedema: May exacerbate,Porphyria: May exacerbate
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer),Active DVT, PE, or history of these conditions,Active or recent arterial thromboembolic disease (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hepatic impairment or disease,Known or suspected pregnancy,Hypersensitivity to estradiol or any component of the product
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Grapefruit and grapefruit juice may increase estradiol systemic exposure and should be avoided during treatment. No other significant food interactions are known.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Estrogens are not recommended during pregnancy. First trimester: increased risk of congenital anomalies (e.g., cardiovascular defects, limb reduction). Second/third trimester: fetal harm including vaginal adenosis, cervical erosion, and possible transplacental carcinogenesis. Use is contraindicated in pregnancy.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Estradiol is excreted in breast milk in small amounts. The milk-to-plasma ratio is estimated at 0.2-0.4. Limited data suggest no adverse effects in nursing infants at typical doses, but caution is advised due to potential for reduced milk production. Use only if clearly needed.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Not applicable; drug is contraindicated in pregnancy. No dose adjustment studies exist due to contraindication.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
ELESTRIN (estradiol vaginal gel) is a bioidentical estradiol formulation for moderate-to-severe dyspareunia due to vulvar and vaginal atrophy. Apply exactly at the applicator mark; overapplication does not increase efficacy but raises systemic absorption. Use the lowest effective dose for the shortest duration. Contraindicated in undiagnosed vaginal bleeding, breast cancer (known/suspected), or estrogen-dependent neoplasia.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Apply the gel at the same time each day, using the provided applicator to the exact fill line.,Do not use more than prescribed; more gel does not improve symptoms and increases systemic estrogen exposure.,Wash hands immediately after application; avoid contact with others (especially men, children, pets) until the gel dries.,Report any unexpected vaginal bleeding, breast lumps, or signs of thromboembolism (chest pain, leg swelling, sudden headache) to your healthcare provider.,If you are a smoker over 35, you have an increased risk of serious cardiovascular side effects; discuss smoking cessation with your doctor.,Do not use vaginal lubricants or other products within 30 minutes before or after applying ELESTRIN, as they may interfere with absorption.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELESTRIN vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
ELESTRIN is a Estrogen Replacement Therapy that works by Estradiol is a hormone that binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, leading to effects such as endometrial growth, breast development, and regulation of the menstrual cycle. It also has non-genomic actions via membrane-associated estrogen receptors.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELESTRIN and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELESTRIN is: Apply 1.25 g (2 actuations) of 0.06% gel to upper arm/shoulder once daily; may adjust based on response.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELESTRIN and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELESTRIN is classified as Category C. Estrogens are not recommended during pregnancy. First trimester: increased risk of congenital anomalies (e.g., cardiovascular defects, limb reduction). Second/third trimester: feta. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.